By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
NuView Life Sciences Inc. Enters Global Licensing Agreement With Otsuka Pharmaceutical Co., Ltd. 9/17/2014 8:53:55 AM
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Submit New Drug Application In The US For Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depressive Disorder 7/14/2014 8:24:21 AM
Otsuka Pharmaceutical Co., Ltd. Release: New Once-Monthly Treatment For Schizophrenia, ABILIFY MAINTENA™ (Aripiprazole For Prolonged Release Injectable Suspension), Now Available In Canada 5/5/2014 8:43:26 AM
H. Lundbeck A/S (LUN.CO) And Otsuka Pharmaceutical Co., Ltd. Release: Caregivers Of People With Schizophrenia Need Support, Not Stigma 5/1/2014 4:07:06 PM
FDA Accepts For Review Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Supplemental New Drug Application To Expand Abilify Maintena® (Aripiprazole) Labelling 4/30/2014 10:12:03 AM
Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (ESALF.PK) (U.S.) 3/31/2014 8:21:36 AM
IBM Corporation (IBM) And Otsuka Pharmaceutical Co., Ltd. Develop Transformative Care Coordination Solution 3/26/2014 10:09:14 AM
Otsuka Pharmaceutical Co., Ltd.'s Samsca® Approved In Japan As The World's First Drug Therapy For ADPKD, A Rare Kidney Disease 3/24/2014 8:53:20 AM
Otsuka SA And The Union Announce Global TB Research & Innovation Award 3/19/2014 10:09:42 AM
H. Lundbeck A/S (LUN.CO) And Otsuka Pharmaceutical Co., Ltd. Initiate European Launch Of Abilify Maintena® (Aripiprazole), A Once-Monthly Formulation For The Treatment Of Schizophrenia 3/17/2014 9:02:15 AM
12345678910...
//-->